Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exxenterol is a plant-derived fiber extract developed by Exxentia Grupo Fitoterapéutico, S.A. (Spain), derived from the carob bean (*Ceratonia siliqua*). It is composed of approximately 90% insoluble fiber and 80% insoluble polyphenols. Classified as a phytotherapeutic or nutraceutical product, it is primarily indicated for the reduction of serum total and LDL cholesterol levels in adults with moderate hypercholesterolemia. The product's mechanism of action is attributed to the cholesterol-lowering properties of its insoluble dietary fiber and polyphenol content, which are believed to interfere with cholesterol absorption or metabolism. It has been evaluated in a Phase 2 dose-finding clinical trial in Spain to establish the optimal therapeutic dose for cholesterol reduction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Exxenterol.